| Indicatie: | |
| Studie: | HO181 |
| Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy
followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2Arearranged
or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a
double-blind phase 3 study |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | |
| Studie: | Hibiscus2 |
| A global phase 3, randomised, double-blind and placebo-controlled
study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | |
| Studie: | TAK-079-3002 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and
Safety of Mezagitamab Subcutaneous Injection in Participants with Persistent or Chronic
Primary Immune Thrombocytopenia |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | ≥ 18 jr, fit |
| Studie: | HO501 |
| A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | |
| Studie: | HO165 |
| Phase 2 study of venetoclax treatment (26 cycles) with 6 cycles or 26 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or Small Lymphocytic Lymphoma (AETHER)”. |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | |
| Studie: | HO170 |
| ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell lymphoma: a phase III national multicenter prospective randomized open-label trial |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | ≥ 18 jr, niet fit |
| Studie: | HO177 |
| Randomized study assessing azacitidine and venetoclax with or without revumenib in adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | ≥ 18 jr, niet fit |
| Studie: | HO173 |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | >18 years old, diagnosed with MM |
| Studie: | Hovon 174 - FABULOUS |
| FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – the FABULOUS study |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Patients with newly diagnosed AML who are not considered candidates for intensive treatment regimens |
| Studie: | Hovon 171 |
| A single arm phase II trial to assess cobicistat boosted venetoclax in combination with azacitidine (sc) in patients with newly diagnosed acute myeloid leukaemia (AML) who are not considered candidates for intensive treatment regimens |
| Open in: | HAGA
LUMC |
| Contact: | researchhematologie@hagaziekenhuis.nl; P.A.von_dem_Borne@lumc.nl |
| Status: | OPEN |
|
